Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Silvia Menegatti

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Frontiers in Immunology|April 4, 2019
Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment ResponsesSilvia Menegatti, Elisabetta Bianchi, Lars Rogge
Methods in Enzymology|January 18, 2020
Methods to edit T cells for cancer immunotherapyFrancesca Lucibello, Silvia Menegatti, Laurie Menger
The Journal of Experimental Medicine|March 16, 2016
IL-12 drives functional plasticity of human group 2 innate lymphoid cellsAi Ing Lim, Silvia Menegatti, Jacinta Bustamante, et al.
Science Immunology|December 3, 2021
In vivo genome-wide CRISPR screens identify SOCS1 as intrinsic checkpoint of CD4<sup>+</sup> T<sub>H</sub>1 cell responseAurélien Sutra Del Galy, Silvia Menegatti, Jaime Fuentealba, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 28, 2018
Expansion of Interleukin-22- and Granulocyte-Macrophage Colony-Stimulating Factor-Expressing, but Not Interleukin-17A-Expressing, Group 3 Innate Lymphoid Cells in the Inflamed Joints of Patients With SpondyloarthritisIris C J Blijdorp, Silvia Menegatti, Leonike J J van Mens, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 6, 2018
Brief Report: Interleukin-17 Blockade With Secukinumab in Peripheral Spondyloarthritis Impacts Synovial Immunopathology Without Compromising Systemic Immune ResponsesLeonieke J J van Mens, Marleen G H van de Sande, Silvia Menegatti, et al.
Annals of the Rheumatic Diseases|December 3, 2020
Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivoSilvia Menegatti, Vincent Guillemot, Eleonora Latis, et al.
Nature Biomedical Engineering|November 18, 2024
Ablation of FAS confers allogeneic CD3<sup>-</sup> CAR T cells with resistance to rejection by T cells and natural killer cellsSilvia Menegatti, Sheila Lopez-Cobo, Aurelien Sutra Del Galy, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Frontiers in Immunology|April 4, 2019
Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment ResponsesSilvia Menegatti, Elisabetta Bianchi, Lars Rogge
Methods in Enzymology|January 18, 2020
Methods to edit T cells for cancer immunotherapyFrancesca Lucibello, Silvia Menegatti, Laurie Menger
The Journal of Experimental Medicine|March 16, 2016
IL-12 drives functional plasticity of human group 2 innate lymphoid cellsAi Ing Lim, Silvia Menegatti, Jacinta Bustamante, et al.
Science Immunology|December 3, 2021
In vivo genome-wide CRISPR screens identify SOCS1 as intrinsic checkpoint of CD4<sup>+</sup> T<sub>H</sub>1 cell responseAurélien Sutra Del Galy, Silvia Menegatti, Jaime Fuentealba, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 28, 2018
Expansion of Interleukin-22- and Granulocyte-Macrophage Colony-Stimulating Factor-Expressing, but Not Interleukin-17A-Expressing, Group 3 Innate Lymphoid Cells in the Inflamed Joints of Patients With SpondyloarthritisIris C J Blijdorp, Silvia Menegatti, Leonike J J van Mens, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 6, 2018
Brief Report: Interleukin-17 Blockade With Secukinumab in Peripheral Spondyloarthritis Impacts Synovial Immunopathology Without Compromising Systemic Immune ResponsesLeonieke J J van Mens, Marleen G H van de Sande, Silvia Menegatti, et al.
Annals of the Rheumatic Diseases|December 3, 2020
Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivoSilvia Menegatti, Vincent Guillemot, Eleonora Latis, et al.
Nature Biomedical Engineering|November 18, 2024
Ablation of FAS confers allogeneic CD3<sup>-</sup> CAR T cells with resistance to rejection by T cells and natural killer cellsSilvia Menegatti, Sheila Lopez-Cobo, Aurelien Sutra Del Galy, et al.
Pageof 1